WINNER: Gilead Sciences, CGL and the NHS: Gilead partnering with Drug Treatment Services (and the NHS) to support eliminating Hepatitis C (HCV)
A Patient Access to Care team was deployed to remove barriers and simplify the Hepatitis C referral pathway. It comprised staff training, pathway review and on-site service development.
This led to a 36 per cent increase in HCV testing, 45 per cent increase in referrals, and close to home care delivery.
Finalists:
- Baxter Healthcare and Wessex Cancer Alliance: Review of out of hospital systemic anticancer therapy services across Wessex
- Bayer, Oxford Academic Health Science Network and Buckinghamshire Clinical Commissioning Group: Excellence in AF
- Bayer and Manchester University Foundation Trust: Innovating the delivery and capacity expansion of macular services for the people of Greater Manchester
- Coloplast, Northumberland CCG and NECS: Stoma Partnership Programme
- Health Innovation Manchester and ABPI: UK first memorandum of understanding between the NHS and pharmaceutical industry
- LEO Pharma and ABMU Health Board: Working together to improve the management of CAT patients
- Lilly and City Hospitals Sunderland: Diabetes Inpatient Project
- MSD UK and Suffolk Primary Care: Shingles Immunisation Programme
- Novartis and Chelsea and Westminster Hospital FT: Chelwest Heart Failure Collaborative
- Novartis Oncology and the NHS: Value Based Partnership Working
- Novartis Oncology and University College London Hospital: Multidisciplinary Level Balanced Scorecard Development
For all enquiries with regards to the Partnerships Awards please contact Chris Edwards, Awards Director, HSJ
Winners of the 2019 HSJ Partnership Awards announced

The outstanding work that organisations are doing in partnership with the NHS was recognised with winners named in 16 categories at the 2019 HSJ Partnership Awards.
- 1
- 2
- 3
- 4
- 5
Currently
reading
HSJ Partnership Awards 2019: Best Pharmaceutical Partnership with the NHS
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17














































No comments yet